Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 06/24 03:59:59 pm
69.6 EUR   +1.25%
06/17FRESENIUS SEá : Deutsche Bank reiterates its Neutral rating
MD
06/10FRESENIUS SEá : Buy rating from Goldman Sachs
MD
06/10PRESS RELEASE : SphingoTec Expands Management Team and Appoints new CFO
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE: Fresenius Medical Care delivers solid first quarter in light of the COVID-19 pandemic, confirms outlook for 2021

05/06/2021 | 01:10am EDT
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Quarter Results 
Fresenius Medical Care delivers solid first quarter in light of the COVID-19 pandemic, confirms outlook for 2021 
2021-05-06 / 07:08 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
May 6, 2021 
Fresenius Medical Care delivers solid first quarter in light of the COVID-19 pandemic, confirms outlook for 2021 
- Organic treatment growth impacted by COVID-19 pandemic as expected 
- Reported revenue and earnings continued to be adversely affected by exchange rate effects 
- Earnings development supported by phasing and expected lower SG&A expense anticipated to reverse 
 throughout the year 
- Vaccination of patients accelerated to 51 percent globally 
- Financial targets for FY 2021 confirmed 
Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: "The COVID-19 pandemic continues to plague our 
societies and especially our vulnerable patients. We are very grateful that we are increasingly allowed to directly 
vaccinate our dialysis patients in our clinics. By doing so, we can support healthcare systems, contribute to saving 
lives and overcoming this health crisis as fast as possible. While we have seen significant progress in the roll-out 
and adoption of vaccinations globally, COVID-19 infection rates in several countries remain high. This will, 
unfortunately, continue to affect many of our patients. Consequently, this will also continue to impact our organic 
growth and weigh on our earnings development throughout the year. As the underlying development in the first three 
months was in line with our expectations, we confirm our guidance for the full year 2021." 
Key figures (IFRS) 
                  Q1 2021 Q1 2020 Growth  Growth 
                    EUR m   EUR m    yoy yoy, cc 
Revenue             4,210   4,488    -6%     +1% 
Operating income      474     555   -15%     -8% 
Net income^[1]        249     283   -12%     -6% 
Basic EPS (EUR)      0.85    0.95   -10%     -4% 

cc = at constant currency, EPS = earnings per share

COVID-19 impact on organic growth continues to accumulate as expected

The adverse COVID-19 impact on organic growth in the Health Care Services business amounted to around 350 basis points in the first quarter. While monthly excess mortality continuously declined since February, it is expected to further accumulate and peak in the second quarter.

Besides Fresenius Medical Care's comprehensive measures to reduce infection risks and maintain safe operations in its dialysis centers, vaccinations are crucial for containing the COVID-19 pandemic. In several countries, Fresenius Medical Care has made its dialysis clinics available for the direct vaccination of patients and, where requested, the general public. At the end of March, the U.S. government agreed to directly allocate COVID-19 vaccine to dialysis centers nationwide. At Fresenius Medical Care's U.S. facilities, more than 64% of patients and 47% of dialysis center staff have been at least partially vaccinated. The Company is making further progress every day. On a global basis, about 51 percent of Fresenius Medical Care's patients have received at least one vaccination.

Outlook

Fresenius Medical Care confirms its outlook for FY 2021 as outlined on February 23, 2021. The Company expects revenue to grow at a low- to mid-single digit percentage rate and net income to decline at a high-teens to mid-twenties percentage rate against the 2020 base.^[2]

The Company continues to monitor closely the latest COVID-19-related developments in respect to additional variants of the virus and potential surges in different regions.

Fresenius Medical Care will experience an adverse earnings effect due to the U.S. government delaying the CKCC models (Comprehensive Kidney Care Contracting) by nine months to January 1, 2022. This effect will be offset by the further extension of the U.S. Medicare sequestration relief from April 1, 2021 until the end of 2021.

To support its 2025 strategy, further strengthen profitability and compensate for the negative earnings effects of the COVID-19 pandemic, Fresenius Medical Care has initiated the FME25 program. The Company is currently undergoing a detailed review of its global operating model and will provide an update in the second half of 2021.

Driving value-based care

Fresenius Medical Care aims to build sustainable partnerships with payors to support the transition from a fee-for-service to a pay-for-performance healthcare system. This applies equally to reimbursement models of commercial and public insurers. In the U.S., Fresenius Medical Care recently extended its value-based arrangement with Aetna, Inc., a provider of health insurance and related services and subsidiary of CVS Health Corporation, to include patients enrolled in Medicare Advantage. In late 2020, Fresenius Medical Care expanded its cooperation with health insurer Humana and thereby implemented the existing clinical network contract as a value-based payment model.

Revenue and earnings impacted by COVID-19 and exchange rate effects

Revenue declined by 6% to EUR 4,210 million (+1% at constant currency). Organic growth amounted to 1%.

Health Care Services revenue decreased by 7% to EUR 3,325 million (+1% at constant currency, +1% organic). The decline was mainly due to a negative exchange rate effect, the absence of a prior-year partial reversal of a revenue recognition adjustment, the impact from COVID-19 and lower reimbursement for calcimimetics.

Health Care Products revenue declined by 1% to EUR 885 million (+4% at constant currency, +5% organic). Headwinds from exchange rates and lower sales of acute care products as well as in-center disposables were partially offset by higher sales of machines for chronic treatment, peritoneal dialysis products and home hemodialysis products.

Operating income decreased by 15% to EUR 474 million (-8% at constant currency), resulting in a margin of 11.3% (Q1 2020: 12.4%). The decrease was mainly driven by effects from COVID-19 across all regions, higher personnel expenses and a significant negative exchange rate effect. In addition, operating income was negatively affected by a positive prior-year effect from the divestiture of cardiovascular clinics and a prior-year partial reversal of a revenue recognition adjustment. These negative effects were partially offset by an improved payor mix, mainly driven by Medicare Advantage, and expected lower SG&A expense, which are anticipated to reverse in the remainder of the year.

Net income^1 declined by 12% to EUR 249 million (-6% at constant currency). Besides the above-mentioned operating earnings effects, net income was supported by a 27% decrease of net interest expense to EUR 76 million (Q1 2020: EUR 104 million).

The first quarter 2020 included negative COVID-19 effects that reversed in Q2 2020, including the compensation received under the CARES Act, and therewith increase the base for the second quarter 2021. These base effects impact the phasing of net income growth in 2021.

Basic earnings per share (EPS) decreased by 10% to EUR 0.85 (-4% at constant currency). The decline as a result of the above-mentioned earnings effects was partially offset by a decrease in the average weighted number of shares outstanding due to the redemption of shares following the completed share buyback program.

Cash flow development

Fresenius Medical Care generated EUR 208 million of operating cash flow (Q1 2020: EUR 584 million), resulting in a margin of 4.9% (Q1 2020: 13.0%). The decline was driven by the seasonality in invoicing and periodic delays in payment of public health care organizations.

Free cash flow^[3] amounted to EUR 29 million (Q1 2020: EUR 304 million), resulting in a margin of 0.7% (Q1 2020: 6.8%).

Regional developments

In North America, revenue declined by 9% to EUR 2,899 million (-1% at constant currency, -1% organic). Besides a sizable negative exchange rate effect, this was mainly due to a substantial negative impact of COVID-19 on the Services business and lower reimbursement for calcimimetics.

Operating income in North America declined by 14% to EUR 399 million (-6% at constant currency), resulting in a margin of 13.7% (Q1 2020: 14.5%). The decrease was mainly due to the effects of COVID-19, higher personnel expense, headwinds from exchange rates, a positive prior-year effect from the divestiture of cardiovascular clinics, a prior-year partial reversal of a revenue recognition adjustment and a lower contribution from calcimimetics. This was mitigated by an improved payor mix, mainly driven by an increased Medicare Advantage share, contributions from acquisitions and lower SG&A expense due to favorable phasing.

Revenue in EMEA decreased by 1% and amounted to EUR 670 million (+1% at constant currency, +1% organic). This was mainly driven by the unfavorable effects of COVID-19 and negative exchange rate effects.

Operating income in the EMEA region declined by 21% to EUR 80 million (-21% at constant currency), resulting in a margin of 11.9% (Q1 2020: 14.9%). The prior-year base benefitted from the revaluation of an investment. In addition, the decline was mainly driven by an unfavorable country mix in the Products business, a decrease in dialysis days as well as higher cost for personnel and supplies in certain countries. This was partially offset by lower bad debt expense.

In Asia-Pacific, revenue increased by 6% to EUR 471 million (+10% at constant currency, +11% organic), mainly due to organic growth in the Services and Product businesses as well as contributions from acquisitions. This was partially offset by the effect of clinics closed or sold in the prior year.

(MORE TO FOLLOW) Dow Jones Newswires

May 06, 2021 01:09 ET (05:09 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH CORPORATION 0.05% 83.77 Delayed Quote.22.59%
DJ INDUSTRIAL 0.95% 34196.82 Delayed Quote.10.68%
FRESENIUS MEDICAL CARE AG & CO. KGAA 1.25% 69.6 Delayed Quote.2.05%
FRESENIUS SE & CO. KGAA 0.01% 43.98 Delayed Quote.16.23%
HUMANA INC. 0.52% 440.73 Delayed Quote.6.21%
ZR (ZR) - CBE (ELECTRONIC)/C1 -0.82% 13.235 End-of-day quote.6.05%
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
06/17FRESENIUS SEá : Deutsche Bank reiterates its Neutral rating
MD
06/10FRESENIUS SEá : Buy rating from Goldman Sachs
MD
06/10PRESS RELEASE : SphingoTec Expands Management Team and Appoints new CFO
DJ
06/09DGAP-DD : Fresenius Medical Care AG & Co. KGaA english
DJ
06/08FMC FRESENIUS MEDICAL CARE AG & CO K : Goldman Sachs reiterates its Buy rating
MD
06/07PRESS RELEASE : MagForce AG Supports World Brain Tumor Day and Informs about Var..
DJ
06/02ANALYST RECOMMENDATIONS : Bank of America, Bodycote, Chevron, Dow Inc, Ferguson...
06/01FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies gives a Sell rating
MD
06/01FMC FRESENIUS MEDICAL CARE AG & CO K : Goldman Sachs maintains a Buy rating
MD
06/01FRESENIUS SEá : Goldman Sachs reaffirms its Buy rating
MD
More news
Financials (USD)
Sales 2021 21 617 M - -
Net income 2021 1 345 M - -
Net Debt 2021 13 952 M - -
P/E ratio 2021 18,1x
Yield 2021 1,72%
Capitalization 24 315 M 24 317 M -
EV / Sales 2021 1,77x
EV / Sales 2022 1,66x
Nbr of Employees 124 995
Free-Float 67,8%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 83,02 $
Average target price 82,66 $
Spread / Average Target -0,43%
EPS Revisions
Managers and Directors
NameTitle
Rice Powell Chief Executive Officer
Helen Giza Chief Financial Officer
Dieter Schenk Chairman-Supervisory Board
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors